Jason B. Kaplan

Hematology
2650 Ridge Ave
Evanston, IL 60201

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 24, 2025

Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.

Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 31, 2025

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers.

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers.

Journal: ESMO open
Published: March 31, 2025

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 19, 2025

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 31, 2024

Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.

Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.

Journal: Blood advances
Published: July 19, 2023

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Journal: Blood advances
Published: May 16, 2023

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).

Journal: Oncotarget
Published: January 26, 2023

Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma.

Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma.

Journal: EJHaem
Published: September 23, 2022

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.

Journal: Haematologica
Published: April 27, 2022

Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Journal: EJHaem
Published: November 08, 2021

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.

Journal: Leukemia & lymphoma
Published: August 02, 2021
Showing 1-12 of 49

Last Updated: 09/26/2026